Endemic mycoses - are we making progress in management?
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
7
11
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
The endemic fungi are a significant cause of morbidity and mortality in effected patients. The range of endemicity for these are expanding with infections observed outside of traditional locations. Enhanced diagnostic and treatment practices may significantly alter patient outcomes. Recently completed clinical trials have focused on an assessment of improving efficacy while minimizing patient toxicity. Practice changing trials have been completed in histoplasmosis showing the utility of a single up-front liposomal amphotericin B dose followed by standard itraconazole dosing. The recent evaluation of several antifungal options including isauvconazole in the treatment of coccidioidomycosis also show promise for additional therapeutic agents. A recently conducted trial has also shown the superiority of amphotericin B therapy over itraconazole in the treatment of talaromycosis. The increased range of endemic mycoses coupled with the growing immunocompromised patient population mandates continued investigation of improved diagnostic and therapeutic options. Advances in these areas have led to more rapid diagnosis and more efficacious antifungal therapy.
Identifiants
pubmed: 37755392
doi: 10.1097/QCO.0000000000000971
pii: 00001432-202312000-00003
doi:
Substances chimiques
Antifungal Agents
0
Itraconazole
304NUG5GF4
Types de publication
Review
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
436-442Subventions
Organisme : NINDS NIH HHS
ID : K23 NS110470
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI166798
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI170158
Pays : United States
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Thompson GR 3rd, Barker BM, Wiederhold NP. Large-scale evaluation of in vitro amphotericin B, triazole, and echinocandin activity against Coccidioides species from U.S. institutions. Antimicrob Agents Chemother 2017; 61:e02634-16.
Davis MR, Nguyen MH, Donnelley MA, Thompson Iii GR. Tolerability of long-term fluconazole therapy. J Antimicrob Chemother 2019; 74:768–771.
Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 2011; 52:604–611.
Thompson GR 3rd, Bays D, Cohen SH, Pappagianis D. Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles. Antimicrob Agents Chemother 2012; 56:563–564.
Nguyen MH, Davis MR, Wittenberg R, et al. Posaconazole serum drug levels associated with pseudohyperaldosteronism. Clin Infect Dis 2019; 70:2593–2598.
Alpern JD, Bahr NC, Vazquez-Benitez G, et al. Diagnostic delay and antibiotic overuse in acute pulmonary blastomycosis. Open Forum Infect Dis 2016; 3:ofw078.
Miller AC, Arakkal AT, Koeneman SH, et al. Frequency and duration of, and risk factors for, diagnostic delays associated with histoplasmosis. J Fungi (Basel) 2022; 8:438.
Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807–825.
Brodsky AL, Gregg MB, Loewenstein MS, et al. Outbreak of histoplasmosis associated with the 1970 Earth Day activities. Am J Med 1973; 54:333–342.
Chamany S, Mirza SA, Fleming JW, et al. A large histoplasmosis outbreak among high school students in Indiana, 2001. Pediatr Infect Dis J 2004; 23:909–914.
Goodwin RA Jr, Snell JD Jr. The enlarging histoplasmoma. Concept of a tumor-like phenomenon encompassing the tuberculoma and coccidioidoma. Am Rev Respir Dis 1969; 100:1–12.
Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther 2006; 6:1207–1221.
Goodwin RA, Loyd JE, Des Prez RM. Histoplasmosis in normal hosts. Medicine (Baltimore) 1981; 60:231–266.
Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992; 93:489–497.
Wheat LJ, Azar MM, Bahr NC, et al. Histoplasmosis. Infect Dis Clin North Am 2016; 30:207–227.
Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105–109.
Pasqualotto AC, Dalla Lana D, Godoy CSM, et al. Single high-dose of liposomal amphotericin B in HIV/AIDS-related disseminated histoplasmosis: a randomized trial. Clin Infect Dis 2023; [Online ahead of print].
Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995; 98:336–342.
Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118:610–616.
Hecht FM, Wheat J, Korzun AH, et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:100–107.
Wheat LJ, Connolly P, Smedema M, et al. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis 2001; 33:1910–1913.
Wheat LJ, Connolly P, Smedema M, et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother 2006; 57:1235–1239.
Spec A, Connolly P, Montejano R, Wheat LJ. In vitro activity of isavuconazole against fluconazole-resistant isolates of Histoplasma capsulatum . Med Mycol 2018; 56:834–837.
Lamoth F, Mercier T, Andre P, et al. Isavuconazole brain penetration in cerebral aspergillosis. J Antimicrob Chemother 2019; 74:1751–1753.
Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole treatment of Cryptococcosis and dimorphic mycoses. Clin Infect Dis 2016; 63:356–362.
Majdick K, Kaye K, Shorman MA. Central nervous system blastomycosis clinical characteristics and outcomes. Med Mycol 2021; 59:87–92.
de Oliveira VF, Kruschewsky WLL, Sekiguchi WK, et al. Clinical, radiological and laboratory characteristics of central nervous system histoplasmosis: a systematic review of a severe disease. Mycoses 2023; 66:659–670.
Restrepo A, Tobon A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54:319–327.
Calcagno A, Baietto L, De Rosa FG, et al. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. J Antimicrob Chemother 2011; 66:224–225.
FDA. TOLSURA (itraconazole capsule), for oral use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208901s000lbl.pdf [Accessed June 6, 2023].
McKinsey DS, Kauffman CA, Pappas PG, et al. Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1996; 23:996–1001.
Wheat LJ, Connolly P, Haddad N, et al. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrob Agents Chemother 2002; 46:248–250.
Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med 1997; 103:223–232.
Hendrix MJ, Larson L, Rauseo AM, et al. Voriconazole versus itraconazole for the initial and step-down treatment of histoplasmosis: a retrospective cohort. Clin Infect Dis 2021; 73:e3727–e3732.
Freifeld A, Proia L, Andes D, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009; 53:1648–1651.
Wolf J. Is itraconazole superior to voriconazole for treatment of histoplasmosis? J Pediatr Infect Dis Soc 2021; 10:940.
Hage CA, Connolly P, Horan D, et al. Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum . Antimicrob Agents Chemother 2011; 55:4447–4450.
Kobayashi K, Asakura T, Kawada I, et al. Disseminated histoplasmosis from a calcified lung nodule after long-term corticosteroid therapy in an elderly Japanese patient: a case report. Medicine 2019; 98:e15264.
Myint T, Chow FC, Bloch KC, et al. Detection of (1,3)-beta- d -glucan in cerebrospinal fluid in Histoplasma meningitis. J Clin Microbiol 2018; 56:e00663-18.
Datta K, LaRue R, Permpalung N, et al. Development of an interferon-gamma release assay (IGRA) to aid diagnosis of histoplasmosis. J Clin Microbiol 2022; 60:e0112822.
Ampel NM, Giblin A, Mourani JP, Galgiani JN. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. Clin Infect Dis 2009; 48:172–178.
Blair JE, Chang YH, Cheng MR, et al. Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis. Emerg Infect Dis 2014; 20:983–990.
Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005; 41:1217–1223.
Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis 2016; 63:e112–e146.
Thompson GR 3rd, Lewis JS 2nd, Nix DE, Patterson TF. Current concepts and future directions in the pharmacology and treatment of coccidioidomycosis. Med Mycol 2019; 57: (Suppl 1): S76–S84.
Prabhu RM, Bonnell M, Currier BL, Orenstein R. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis 2004; 39:e74–e77.
Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 2011; 53:1060–1066.
Heidari A, Quinlan M, Benjamin DJ, et al. Isavuconazole in the treatment of Coccidioidal meningitis . Antimicrob Agents Chemother 2019; 63:e02232-18.
Bercovitch RS, Catanzaro A, Schwartz BS, et al. Coccidioidomycosis during pregnancy: a review and recommendations for management. Clin Infect Dis 2011; 53:363–368.
Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:1801–1812.
Bradsher RW. Histoplasmosis and blastomycosis. Clin Infect Dis 1996; 22: (Suppl 2): S102–S111.
Chowfin A, Tight R, Mitchell S. Recurrent blastomycosis of the central nervous system: case report and review. Clin Infect Dis 2000; 30:969–971.
Schwartz IS, Embil JM, Sharma A, et al. Management and outcomes of acute respiratory distress syndrome caused by blastomycosis: a retrospective case series. Medicine 2016; 95:e3538.
Miller R, Assi M. Practice ASTIDCo. Endemic fungal infections in solid organ transplant recipients – guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13553.
Ta M, Flowers SA, Rogers PD. The role of voriconazole in the treatment of central nervous system blastomycosis. Ann Pharmacother 2009; 43:1696–1700.
Borgia SM, Fuller JD, Sarabia A, El-Helou P. Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Med Mycol 2006; 44:659–664.
Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis 2005; 40:e69–e71.
Panicker J, Walsh T, Kamani N. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2006; 25:377–379.
Scolarici MJ, King C, Sterkel A, et al. The role of isavuconazonium sulphate for the treatment of blastomycosis: a case series and antifungal susceptibility. Open Forum Infect Dis 2022; 9:ofac220.
Mehta TI, Kurman J, Dolan S, et al. Blastomycosis in solid organ transplant recipients – a retrospective series from southeastern Wisconsin. Transpl Infect Dis 2021; 23:e13671.
Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1995; 20:267–271.
Pappas PG, Bradsher RW, Kauffman CA, et al. Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1997; 25:200–205.
Proia LA, Harnisch DO. Successful use of posaconazole for treatment of blastomycosis. Antimicrob Agents Chemother 2012; 56:4029.
Hanna JJ, Guastadisegni JM, Kouma MA, et al. Blastomycosis presenting with acute airway obstruction from a retropharyngeal abscess and complicated by severe hypokalemia during posaconazole therapy: a case report and review of literature. Open Forum Infect Dis 2022; 9:ofac414.
Hussaini SMQ, Madut D, Tong BC, et al. Pulmonary blastomycosis presenting as primary lung cancer. BMC Infect Dis 2018; 18:336.
Day SR, Weiss DB, Hazen KC, Moore CC. Successful treatment of osseous blastomycosis without pulmonary or disseminated disease and review of the literature. Diagn Microbiol Infect Dis 2014; 79:242–244.
Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996; 40:1314–1316.
Nakai T, Uno J, Ikeda F, et al. In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003; 47:1376–1381.
Mardini J, Nguyen B, Ghannoum M, et al. Treatment of chronic pulmonary blastomycosis with caspofungin. J Med Microbiol 2011; 60 (Pt 12):1875–1878.
de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R, et al. Treatment of cutaneous sporotrichosis with itraconazole--study of 645 patients. Clin Infect Dis 2011; 52:e200–e206.
Conti Diaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992; 35:153–156.
Francesconi G, Francesconi do Valle AC, Passos SL, et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia 2011; 171:349–354.
Rodriguez CHV, Canataro PA, Abusamra L, et al. Oral terbinafine and itraconazole therapy against Sporothrix brasiliensis an emerging species in Argentina. Mycopathologia 2023; 188:287–289.
Thompson GR 3rd, Le T, Chindamporn A, et al. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. Lancet Infect Dis 2021; 21:e364–e374.
Le T, Kinh NV, Cuc NTK, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. N Engl J Med 2017; 376:2329–2340.
Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339:1739–1743.
Li Z, Yang J, Qiu Y, et al. Disseminated Talaromyces marneffei infection with STAT3-Hyper-IgE syndrome: a case series and literature review. Open Forum Infect Dis 2023; 10:ofac614.
Guo P, Chen W, Chen S, et al. The delayed clearance of Talaromyces marneffei in blood culture may be associated with higher MIC of voriconazole after antifungal therapy among AIDS patients with talaromycosis. PLoS Negl Trop Dis 2023; 17:e0011201.
Zhou Y, Qin Y, Lu Y, et al. Efficacy and safety of voriconazole versus amphotericin B deoxycholate induction treatment for HIV-associated talaromycosis: a prospective multicenter cohort study in China. Infect Dis Ther 2022; 11:1575–1590.
Lang Q, Pasheed Chughtai A, Kong WF, Yan HY. Case report: successful treatment of pulmonary talaromyces marneffei infection with posaconazole in a renal transplant recipient. Am J Trop Med Hyg 2020; 104:744–747.